The difference between fumetinib and osimertinib

Osimertinib and Gefitinib are targeted drugs used to treat non-small cell lung cancer. Fumetinib is a first-generation EGFR tyrosine kinase inhibitor that blocks the growth signaling of cancer cells by inhibiting the tyrosine kinase activity on the EGFR receptor. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that not only inhibits abnormal signaling caused by EGFR mutations, but also plays a targeted role in the resistance mutation T790M of common EGFR mutations.

Fumetinib is mainly used for the treatment of EGFR gene mutation-positive advanced or metastatic non-small cell lung cancer. Osimertinib is mainly used for EGFR gene mutation-positive non-small cell lung cancer, and has replaced first- and second-generation EGFR inhibitors in first-line treatment. The therapeutic effect of fumetinib may lead to resistance in some patients, mainly because the EGFR mutation changes from a sensitive mutation to a resistant mutation (such as T790M mutation). Osimertinib was designed with this resistance mechanism in mind and can effectively inhibit resistance caused by the T790M mutation.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.